<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02146274</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00049705</org_study_id>
    <nct_id>NCT02146274</nct_id>
  </id_info>
  <brief_title>Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research</brief_title>
  <acronym>PROSPER</acronym>
  <official_title>Observational Study of Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROSPER (Patient-centered Research into Outcomes Stroke patients Prefer and Effectiveness
      Research) is a three year research project to create a national, sustainable model to improve
      decision-making and patient-centered stroke outcomes through comparative effectiveness
      research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to address existing evidence gaps and develop the requested data on the range of
      clinical outcomes that may be experienced by stroke survivors. To achieve these goals, we
      will link the nation's largest stroke registry, the American Heart Association (AHA) Get With
      The Guidelines-Stroke program and nationwide Medicare claims data, coupled with telephone
      interviews for longitudinal treatment and downstream patient-reported outcomes.

      Design &amp; Procedures:

      Retrospective: Using GWTG-Stroke database and its associated 1900 hospitals, we will conduct
      several comparative research protocols prioritized by stroke survivor focus groups and
      surveys. GWTG-Stroke registry clinical data linked with Medicare claims will be used for
      analysis of effectiveness and safety of post-stroke therapies on long-term clinical outcomes
      (n= 450,000). Outcomes of interest include:

      &quot;Home-time&quot; (days alive and at home) Death Stroke/TIA readmission All-cause readmission
      Cardiovascular readmission Bleeding readmission

      Prospective:

      We will use the existing AVAIL registry combined with an additional 2000 stroke survivors for
      a combined cohort of over 5000 patients to obtain detailed information on patient-reported
      outcomes. The AVAIL Registry (IRB # Pro00012243) collected data from 3000 stroke survivors
      between 2006 and 2008. We plan to use these data to supplement our prospective PROSPER study.
      The PROSPER study will enroll a minimum of 2,000 subjects to augment the data collected from
      the AVAIL study. Consented patients from at least 75 sites will complete interviews at 3 and
      6 months after discharge. We anticipate that the PROSPER questionnaire will include the
      following tools: Fatigue Severity Scale (FSS), Patient Health Questionnaire (PHQ8), modified
      Rankin scale (mRS), Barthel Index, EuroQOL (EQ-5D), Stroke-specific quality of life
      (SSQOL-12) and Lawton Instrumental Activities of Daily Living (IADL). Sites will consent
      interested patients and have them complete a patient contact information form which includes,
      name, address, phone numbers, email address, etc. Outcomes of interest include: : Post-stroke
      fatigue, Depression, Chronic pain, Medication intolerance, Modified Rankin scale (mRS),
      EuroQOL and Stroke-specific quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>Patient Health Questionnaire - 2 Item (PHQ-2) Higher score suggests more depression; range of 0-6. A score of two or higher suggests a diagnosis of major depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Status</measure>
    <time_frame>6 months after enrollment</time_frame>
    <description>Euro-QOL ver. 5D-3L (EQ 5D-3L) EQ-5D-3L Five level version of the Euro-QOL. Index Value ranging from 0-1.0 Higher scores indicate better functioning</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1877</enrollment>
  <condition>Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Ischemic Stroke Patients</arm_group_label>
    <description>Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Ischemic Stroke patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consistent with GWTG inclusion criteria, patients must be older than 18 and have a
             primary diagnosis of acute ischemic stroke.

          -  Ability to give informed consent or the availability of a surrogate who can consent on
             the patient's behalf.

        Exclusion Criteria:

          -  Patients with subarachnoid or intracerebral hemorrhage

          -  Patients with transient ischemic attack (TIA)

          -  Patients with expected survival less than 6 months/discharged to hospice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DCRI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Clinical Research Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2014</study_first_posted>
  <results_first_submitted>March 5, 2018</results_first_submitted>
  <results_first_submitted_qc>May 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>August 2, 2019</last_update_submitted>
  <last_update_submitted_qc>August 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PROSPER</keyword>
  <keyword>Stroke</keyword>
  <keyword>Ischemic Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02146274/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02146274/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Observational survey</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ischemic Stroke Patients</title>
          <description>Patients who have had an ischemic stroke</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1877"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1804"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Exclusions (Total N, # of sites, %, # excluded):
Interviewed PROSPER patients with registry data 1,804 63
Active patient status 1,715 62 95.1 -89
Medical history panel &gt;75% complete 1,652 60 96.3 -63
Ischemic stroke as primary diagnosis 1,622 60 98.2 -30
Exclude expired/left AMA/disposition UTD/missing 1,617 60 99.7 -5</population>
      <group_list>
        <group group_id="B1">
          <title>Ischemic Stroke Patients</title>
          <description>Patients who have had an ischemic stroke</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1617"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="55" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="760"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>race</title>
              <category_list>
                <category>
                  <title>white</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1229"/>
                  </measurement_list>
                </category>
                <category>
                  <title>black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                  </measurement_list>
                </category>
                <category>
                  <title>hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>other/utd</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antidepressant at Discharge</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Antidepressant - Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Antidepressant - No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Depression</title>
        <description>Patient Health Questionnaire - 2 Item (PHQ-2) Higher score suggests more depression; range of 0-6. A score of two or higher suggests a diagnosis of major depression.</description>
        <time_frame>6 months after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Stroke Patients By Anti-depressant =Yes</title>
            <description>Patients on Antidepressant at Discharge</description>
          </group>
          <group group_id="O2">
            <title>Ischemic Stroke Patients By Anti-depressant =No</title>
            <description>Patients not on Antidepressant at Discharge</description>
          </group>
        </group_list>
        <measure>
          <title>Depression</title>
          <description>Patient Health Questionnaire - 2 Item (PHQ-2) Higher score suggests more depression; range of 0-6. A score of two or higher suggests a diagnosis of major depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="1432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".7" spread=".22"/>
                    <measurement group_id="O2" value=".79" spread=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status</title>
        <description>Euro-QOL ver. 5D-3L (EQ 5D-3L) EQ-5D-3L Five level version of the Euro-QOL. Index Value ranging from 0-1.0 Higher scores indicate better functioning</description>
        <time_frame>6 months after enrollment</time_frame>
        <population>Comparing functional status of ischemic stroke patients who are and are not taking an antidepressant 6 months post enrollment</population>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Stroke Patients on Antidepressant (n=222)</title>
            <description>Ischemic stroke patients taking an antidepressant</description>
          </group>
          <group group_id="O2">
            <title>Ischemic Stroke Patients Not Taking an Antidepressant (n=760)</title>
            <description>Ischemic stroke patients not taking an antipressant.</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status</title>
          <description>Euro-QOL ver. 5D-3L (EQ 5D-3L) EQ-5D-3L Five level version of the Euro-QOL. Index Value ranging from 0-1.0 Higher scores indicate better functioning</description>
          <population>Comparing functional status of ischemic stroke patients who are and are not taking an antidepressant 6 months post enrollment</population>
          <units>score on scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="760"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.47" upper_limit="0.83"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.71" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Not collected; observational study</time_frame>
      <desc>Not collected; observational study</desc>
      <group_list>
        <group group_id="E1">
          <title>Ischemic Stroke Patients</title>
          <description>Patients who have had an ischemic stroke that are hospitalized in an acute-care setting.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>6 month prospective observational study. Patients not randomized</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice Dean of Clinical Research</name_or_title>
      <organization>Duke University School of Medicine</organization>
      <phone>919-684-4979</phone>
      <email>awindham@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

